Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
(b) Resignation of Principal Accounting
Effective as of December 31, 2020, Yi Ching Yau, the Companys current Chief Accounting Officer, resigned
from her role as principal accounting officer. Ms. Yau will continue in her role as Chief Accounting Officer.
Designation of Principal Accounting Officer
Effective January 1, 2021, the Board of Directors of BridgeBio
Pharma, Inc. (the Company) designated Brian C. Stephenson, Ph.D., CFA, the Companys current Chief Financial Officer and principal financial officer, as its principal accounting officer, as such term is used for purposes
of the rules and regulations of the Securities and Exchange Commission. Dr. Stephenson, age 40, will oversee the Companys accounting matters.
Dr. Stephenson has served in his current role as the Companys Chief Financial Officer and principal financial officer since October 2018. Prior to
joining the Company, Dr. Stephenson served as Partner and the Head of Life Sciences for Capital IP Investment Partners, a special situation investment fund, from 2015 to 2018. From 2011 to 2014, Dr. Stephenson was a Director/Vice
President Leerink Partners, an investment bank. Prior to that, Dr. Stephenson was an Engagement Manager at McKinsey & Company, a worldwide management consulting firm. He received his Ph.D. and M.S. degrees in
chemical engineering from the Massachusetts Institute of Technology and his B.S. in chemical engineering from Brigham Young University. Dr. Stephenson is also a Chartered Financial Analyst charterholder.
Dr. Stephenson is party to an Offer Letter, dated October 28, 2018, with BridgeBio Services, Inc., a copy of which is filed as Exhibit 10.20 to our
Registration Statement on Form S-1 (333-231759) filed on June 11, 2019 and incorporated herein by reference. Dr. Stephenson is not receiving any additional
compensation in connection with his designation as principal accounting officer. There are no arrangements or understandings between Dr. Stephenson and any other persons pursuant to which Dr. Stephenson was appointed as principal
accounting officer of the Company. There are also no family relationships between Dr. Stephenson and any director or executive officer of the Company and he has no direct or indirect interest in any transaction or proposed transaction required
to be disclosed pursuant to Item 404(a) of Regulation S-K.